Volume 22 Number 4 November 1995

THE CANADIAN JOURNAL OF Neurological Sciences

LE JOURNAL CANADIEN DES Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association for Child Neurology

With Epival, it can be.

Because Epival has been proven effective in primary generalized epilepsy,[1-3] as well as in partial seizures that secondarily generalize.[4,5*†]

Epival has been associated with little effect on learning and cognition.[6] Drowsiness, visual disturbances, and ataxia are rarely noted[7] — unlike phenytoin and carbamazepine.[8] Epival is generally well tolerated in properly screened patients,[7] causing less GI irritation (nausea, vomiting and indigestion) than valproic acid.[9]

With Epival, your epilepsy patients can be confident that they most likely appear to be just like anyone else. Because there's more to anticonvulsant therapy than seizure control.

THIS SHOULD BE THE ONLY INDICATION THEY HAVE EPILEPSY.

Epival®

(divalproex sodium)

HELPS PUT PATIENTS BACK IN CONTROL.

* For use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal and is useful in primary generalized seizures with tonic-clonic manifestations. EPIVAL may also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures.
† Monitoring of hepatic function and blood coagulation is advised.

PHARMACEUTICAL PRODUCTS DIVISION
ABBOTT LABORATORIES, LIMITED
SAINT-LAURENT, QUÉBEC

Product Monograph available on request.

For prescribing information see pages xviii, xix.

Volume 22 Number 4 November 1995

THE CANADIAN JOURNAL OF Neurological Sciences

LE JOURNAL CANADIEN DES Sciences Neurologiques

Volume 22 Number 4 November 1995

THE CANADIAN JOURNAL OF Neurological Sciences

LE JOURNAL CANADIEN DES Sciences Neurologiques

The official journal of: / La Revue officielle de:

The Canadian Neurological Society
La Société Canadienne de Neurologie

The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie

The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique

The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Congress of Neurological Sciences is at/
Le secrétariat des quatre associations et du Congrès Canadien des Sciences Neurologiques est situe en permanence à:
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is $65 for members; $75 for non-members in Canada; $85 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students $32.50 per annum (members); $37.50 per annum (non-members). Single copies $20 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 810, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575; Fax (403) 229-1661.

Mailed under Publications Mail registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus, Excerpta Medica and Current Contents — Clinical Practice and Life Sciences, Current Awareness in Biological Sciences.*

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 65 $ pour les membres; 75 $ pour les non-membres au Canada; 85 $ pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 32,50 $ par année (membres); 37,50 $ par année (non-membres). Copie simple: 20 $ plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Par courrier: 810, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575; Fax (403) 229-1661.

Posté sous permis de poste-publications no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus, Excerpta Medica et Current Contents — Clinical Practice et Life Sciences, Current Awareness in Biological Sciences.*

Advertising representative/Représentant de publicité:
Sally Gregg, Canadian Journal of Neurological Sciences
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: cjns@canjneurolsci.org

Printer/Imprimeur:
McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

Introducing Pr BETASERON®

The first treatment for relapsing/remitting multiple sclerosis

For an overview of Betaseron
dial 1-800-422-1222, access code 400.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

Clinical trials have shown that:

- *The frequency of exacerbations was reduced by approximately 30%*[1]
- *Moderate and severe exacerbations were reduced by 50%*[1]
- *Disease activity, as measured by MRI, was reduced significantly*[2]
- *There was a low incidence of serious side effects*[1]
- *Patient education about common side effects such as injection-site reactions and flu-like symptoms is key to compliance*

Over 40,000 patients treated to date[3]

Pr BETASERON®
INTERFERON BETA-1b
FOR SC INJECTION

Maintaining Independence

For brief prescribing information see pages xxiv, xxv.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

For brief prescribing information see pages xxvi, xxvii.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

range of seizure types, side-effect profile



Many patients with epilepsy – across a wide range of seizure types – are unsatisfactorily controlled with conventional therapies.[1] Now there's LAMICTAL, a novel antiepileptic drug (AED) that is chemically unrelated to all other AEDs in current use.[1,2]

Clinical trials and worldwide experience in over 140,000 patients[3] have shown that adjunctive therapy with LAMICTAL offers a wide range of activity in the management of epilepsy for patients who are not satisfactorily controlled by conventional therapies.[1-24] In fact, LAMICTAL has been shown to render patients seizure-free[4-6,25] or to reduce seizure frequency[1,6,10,15-17,23,25] and severity in up to 65% of patients.[1,6,16,23,25] LAMICTAL has demonstrated a more favourable CNS side-effect profile in healthy volunteers compared to phenytoin.[26] Incidence of somnolence was 13% for LAMICTAL compared to 12% for placebo in pooled results of four double-blind, placebo-controlled studies.[7] Moreover, the majority of patients taking LAMICTAL will not experience unwanted CNS-related side effects.[5†] More of your refractory patients will feel better on LAMICTAL.[6,23]

LAMICTAL has activity across a wide range of seizure types. You can now offer your patients proven tolerability with a low CNS side-effect profile.[†] When faced with refractory patients, choose LAMICTAL – in 25- , 100- or 150-mg strengths – as your first add-on therapy.[†]

New!

Lamotrigine

Lamictal®

For brief prescribing information see pages xxvi, xxvii.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

tail de types de crises avec secondaires sur le SNC



De nombreux patients souffrant d'épilepsie – dans un vaste éventail de types de crises – ne sont pas contrôlés de façon satisfaisante par les traitements conventionnels[1]. Maintenant, il y a LAMICTAL, un nouvel antiépileptique inédit sans parenté chimique avec aucun autre antiépileptique actuel[1,2].

Les essais cliniques et l'expérience mondiale acquise chez plus de 140 000 patients[3] ont montré qu'en traitement d'appoint, LAMICTAL offre une activité étendue dans le traitement de l'épilepsie chez les patients qui ne sont pas contrôlés de façon satisfaisante avec les traitements conventionnels[1-24]. En fait, LAMICTAL a supprimé les crises[4-6,25] ou diminué leur fréquence[1,6,10,15-17,23,25] et leur gravité chez jusqu'à 65 % des patients[1,6,16,23,25]. Chez des volontaires en santé, LAMICTAL a présenté un profil d'effets secondaires sur le SNC plus favorable que la phénytoïne[26]. L'incidence de somnolence a été de 13 % pour LAMICTAL par rapport à 12 % pour le placebo dans les résultats combinés de quatre études à double insu contrôlées par placebo[7]. De plus, la plupart des patients sous LAMICTAL n'éprouveront pas d'effets indésirables qui affectent le SNC[5†]. Un plus grand nombre de vos patients réfractaires se sentiront donc mieux sous LAMICTAL[6,23].

LAMICTAL exerce une activité dans un vaste éventail de types de crises. Vous pouvez maintenant offrir à vos patients un médicament caractérisé par une tolérabilité éprouvée et un profil discret d'effets indésirables sur le SNC[†]. Pour vos patients réfractaires, choisissez LAMICTAL – en 25, 100 ou 150 mg – comme votre premier traitement d'appoint[‡].

Nouveau!

lamotrigine

℗ **Lamictal®**

Pour documentation voir pages xxvi, xxvii.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

Sooner or later, every migra again. Imitrex® believes

A patient who complains about migraine is also complaining about a disrupted life. Indeed, research shows that in at least 31% of attacks, migraine sufferers cannot continue with their daily activities.[1]

That's where *Imitrex*® comes in. For most patients, *Imitrex*® can bring complete relief between 90 minutes and 2 hours, versus up to 9 hours for the usual treatments.*[2,3] *Imitrex*® treats all the symptoms of migraine.**[3-5]



Adapted from *Cephalalgia*: Schoenen 1994.[2]

Unlike conventional remedies, it has not been shown to cause medication-induced headache.[3,6-8] Its adverse events are generally well tolerated, quickly resolved and usually non-threatening when explained to the patient.***[3,7,9] *Imitrex*® may be more expensive, but over 250,000 Canadian patients continue to choose it for migraine relief.[10]

The successful use of *Imitrex*® is most likely in patients who understand its common

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

ine sufferer will feel normal it should be sooner.

side effects, and who know when the drug should be used.***[11] *Imitrex*® should be taken at the start of a debilitating attack, and may also be used after the failure of conventional treatments (except ergotamine-containing preparations).[3]

Most patients have attacks that limit normal function.[1,12] So give your patients† the option of using *Imitrex*®. It's a proven route to a fast recovery.[2]

For more information about *Imitrex*®, please call 1-800-268-0324.

IMITREX®

SUMATRIPTAN SUCCINATE

1994 Winner of the Prix Galien

A faster way back.

Glaxo
Glaxo Canada Inc.

PAAB
CCPP

*Customary treatments include simple analgesics, combination analgesics, ergot derivatives, NSAIDs, narcotics, antiemetics, others.[2] **Head pain, nausea, vomiting, photophobia and phonophobia.[3] ***Fatigue, dizziness, nausea and vomiting have been reported. These side effects are usually mild to moderate in intensity, transient and resolve within 45 minutes of s.c. administration and within two hours of oral administration. *Imitrex*® has been associated with transient chest pain and tightness which may mimic angina pectoris. Only in very rare cases have the symptoms been associated with ischaemic ECG changes. If chest symptoms persist, patient should immediately consult physician.[3] †Contraindicated in patients with ischaemic heart disease, angina pectoris including Prinzmetal angina, previous myocardial infarction and uncontrolled hypertension.[3] *Imitrex*® is a selective 5-HT_1-like receptor agonist.[3]

For brief prescribing information see page xxx.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

The most exciting day for an epileptic patient is one that's totally uneventful.

In terms of seizures, uneventful is exciting. Because it means patients may enjoy life without the constant threat of seizures. And what can make their lives uneventful is new ®SABRIL® (vigabatrin).

As an adjunct for reduction of epileptic seizures, Sabril provides impressive efficacy[1] — with more than a 50% reduction in seizures in up to 60% of patients with uncontrolled complex partial seizures.[2,3,4] In clinical studies, 7-15% of patients actually became seizure free.[5,6]

In over 50 million patient days of worldwide experience, the majority of patients showed no adverse reactions or negative symptoms relating to cognitive function or mood.[4,7,8-12]

Also no serum monitoring is required, which may increase patient compliance. And no significant interaction is reported with other antiepileptics, prescription or over-the-counter medications.*[8,13]

Furthermore, Sabril is designed to inhibit GABA Transaminase, therefore increasing GABA levels.[8]

Sabril. Because when you have epilepsy, there's nothing more exciting than an uneventful day.

Additional control for fewer seizures.

New ®SABRIL®
VIGABATRIN

Neurological function/visual disturbances should be monitored; use with caution in patients with a history of psychosis, in the elderly, in the renally impaired; there could be occupational hazards due to drowsiness; there may be a possible increase in seizures in some patients.[7] *A gradual reduction of about 20% in plasma phenytoin concentration has been observed following add-on therapy with vigabatrin. The mechanism whereby this occurs is unknown. Limited data from clinical trials suggest that increasing the phenytoin dose to compensate may not be necessary.[7]

MARION MERRELL DOW
CANADA
Laval, Quebec H7L 4A8

SABR94-020E PAAB CCPP MEMBER PMAC ®Sabril®. Trademark of Merrell Dow Pharmaceuticals Inc. used under licence.

For brief prescribing information see pages xviii, xix.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press



HE STILL BELIEVES IN MIRACLES.

George Dingman was first diagnosed with Parkinson's when he was thirty-four years old. He's fifty-one today and still active in the community.

He still believes in the unlikely and even the impossible. That's just the way he is – even if it does sound naïve. He just thinks it's healthier to look for possibilities than to accept the way things are. Maybe miracles are too much to expect. But perhaps having a better life with Parkinson's doesn't take a miracle. There's evidence now to suggest that maintaining consistent drug levels can improve the control of Parkinson's – particularly as the disease progresses. It's not exactly a miracle. But, to someone like George, it means hope.

Pr SINEMET® CR 200/50 100/25

(levodopa/carbidopa) CONTROLLED-RELEASE

TREAT TODAY WITH TOMORROW IN MIND

Other patients' experience may differ.

Before prescribing, please consult the attached prescribing information. ®Trademark of Merck & Co., Inc./Merck Frosst Canada Inc., and DuPont Merck Pharma, R.U. PAAB

DUPONT PHARMA

For brief prescribing information see page xvii.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

Pour documentation voir pages xxii, xxiii.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

For brief prescribing information see pages xxii, xxiii.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press

On peut facilement reconnaître le jeune patient épileptique traité au Tegretol® CR.

Excellent contrôle des crises

℗ Tegretol® CR (carbamazépine à libération contrôlée) maîtrise les crises chez de nombreux patients, causant peu d'impact sur la fonction cognitive[1,2]. Tegretol CR permet à de nombreux patients de penser clairement et de donner le meilleur d'eux-mêmes[1,2].

Taux sanguins uniformes

Tegretol CR cause moins de «hauts et de bas» dans les taux sanguins que le Tegretol conventionnel. Les effets secondaires sont ainsi réduits et le modèle de fonction cognitive est plus stable[3].

L'effet indésirable le plus communément signalé, lié à la carbamazépine, est la somnolence. Un tel effet ne se manifeste habituellement que durant la phase initiale du traitement[4] mais on peut réduire son importance en administrant de la carbamazépine à libération contrôlée (TEGRETOL®CR).[1]

Posologie b.i.d. commode

Lorsque vous instituez ou remplacez un traitement, pensez au Tegretol CR. Il est présenté en comprimés à 200 mg et 400 mg facilement divisibles pour une plus grande souplesse d'administration et améliorer l'observance du patient.



TEGRETOL® CR.

Aide les épileptiques à réaliser leur plein potentiel.

Geigy Dorval (Québec) H9S 1B1 ou Mississauga (Ontario) L5N 2W5

PMAC ACIM PAAB CCPP G-95085F

For brief prescribing information see pages xx, xxi.

https://doi.org/10.1017/S0317167100039421 Published online by Cambridge University Press